ORLANDO, Fla., June 8, 2016 /PRNewswire/ -- XaQuil® XR the newest product from XYMOGEN’s medical food* line, Pharmaceutix®, is one of the most exciting products of the year, and the company is racking up the awards to prove it.
In the medical food category, XaQuil XR was recently named this year’s Finished Product of the Year by NutraIngredients and Strategic Product of the Year by Vitafoods.
XYMOGEN Founder and CEO Brian Blackburn says the company developed XaQuil XR using Gnosis’ Quatrefolic® because it provides the natural and metabolically active form of folate, 5-MTHF, and does not require further metabolism.
What that means for patients who require adjunctive treatment for depression specifically, the 70 percent that have a problem converting folic acid to 5-MTHF is that Quatrefolic is better used by the body to help correct low 5-MTHF levels that are associated with depression.
Major depressive disorder (MDD) currently ranks as the fourth leading disease burden worldwide and is expected to become the second largest global disease burden by the year 2020. “The statistics are concerning, and we know that more than half of all patients treated with antidepressant monotherapy fail to experience a remission of their major depressive episode,” Blackburn said. Studies have found that adding folate supplementation to depression treatment has a positive effect on patients.
Pharmaceutix Vice President Duck Williams said it is an honor to be recognized for the contribution the company has made. “We are proud of XaQuil XR’s industry accolades. XaQuil XR is an innovative, extended-release medical food that is incomparable to other products on the market today,” Williams said. “In addition, XaQuil XR costs about 20 percent less than other folate medical food products.”
To learn more about research, products, and services available from XYMOGEN, the family-owned health sciences company that owns Pharmceutix, visit XYMOGEN.com, email pr@xymogen.com, or call (800) 647-6100.
*The United States Food and Drug Administration Title 21 Code of Federal Regulations 101.9(i) (8) states that medical foods are “intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation” (section 5(b)(3) of the Orphan Drug Act (21 U.S.C. 360ee(b)(3)). Such patients may have a limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients, or have other special medically-determined nutrient requirements that cannot be achieved by modification of the normal diet alone.
ABOUT XYMOGEN
XYMOGEN, a family-owned health sciences company headquartered in Orlando, Fla., has been providing high-quality dietary supplements to licensed health care practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who are industry experts in a broad range of specialties. XYMOGEN’s strength as a company has been reinforced eight of the last nine years, as it was recognized again in 2015 by Inc. magazine as one of the 5000 fastest-growing, best-run, most innovative and most inspiring private companies in America. The company’s 136,000 square-foot manufacturing facility is GMP (good manufacturing practices) and GMP for Sport Athletic Banned Substances Program registered by NSF International and TGA Certified. More information is available at www.xymogen.com Please email pr@xymogen.com for comments or inquiries.
Distributed by:
Sara Brady Public Relations, Inc.
222 W. Comstock Avenue, Ste. #204
Winter Park, Florida 32789
For information, contact:
Sara Brady
407-702-6632
sbrady@sarabradypr.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmaceutix-and-gnosis-team-up-to-create-an-award-winning-product-and-help-millions-of-americans-suffering-from-depression-300281957.html
SOURCE XYMOGEN
